Voglibose

drugbox
IUPAC_name = (1"S",2"S",3"R",4"S",5"S")-5-(1,3-dihydroxypropan-2-ylamino)-
1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol

---

CAS_number = 83480-29-9
ATC_prefix = A10
ATC_suffix = BF03
PubChem = 444020
DrugBank =
C = 10 | H = 21 | N = 1 | O = 7
molecular_weight = 267.28 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Voglibose (INN and USAN) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus.

Diabetes is chronic metabolic disorder characterised by hyperglycemia which is due to relative or absolute deficiency of insulin or insulin resistance.

PPHG is termed as Post Prandial Hyperglycemia which is primarily due to first phase insulin secretion. Alpha glucosidase inhibitor is one agent which delays the glucose absorption at the intestine level and thereby prevents sudden surge of glucose post meal.

There are three molecules which belong to this class namely, Acarbose, Miglitol and Voglibose. Voglibose is the latest molecule in this class. Voglibose scores over both Acarbose and MIglitol in terms of potency and side effect profile.

There are several trials supporting the use of Voglibose in the management of PPHG. Also, it has been established that it is PPHG not FPG which is marker of cardiovascular disorders associated with diabetes. So, controlling PPHG is imperative and Voglibose is indicated for the management of PPHG.

External links

* [http://www.voglibose.com voglibose.com]
* [http://www.diabetesincontrol.com diabetesincontrol.com]
* [http://www.diabetesjournals.org diabetesjournals.org]
* [http://www.medicalnewstoday.com/medicalnews.php?newsid=36827 Ranbaxy announcement]